StimOxyGen is a proprietary and world-leading innovative approach to address the global challenge of tumour hypoxia. Hypoxia, or lack of oxygen, is a common characteristic of solid tumours that contributes to the failure of many types of cancer treatment, particularly radiotherapy which relies on oxygen for maximum efficacy. We can solve this longstanding major unmet clinical need by fueling tumours with oxygen to maximise therapeutic effects of radiotherapy.
Total raised: $1.94M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.03.2025 | - | $1.94M | - |
Mentions in press and media 2
| Date | Title | Description |
| 11.03.2025 | StimOxyGen Raises £1.5M in Funding | Sian Farrell (StimOxyGen), Tierna Gillan (R&D Scientist), and Prof Tony McHale (CSO and co-founder) StimOxyGen, a Derry, Northern Ireland, UK-based company developing cancer treatments, raised £1.5M in funding The round was led by DSW V... |
| - | StimOxyGen | “StimOxyGen – StimOxyGen” |